Drugs / Rowachol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01765465 | Jan 2013 → May 2014 | postcholecystectomy syndrome | DongGuk University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06972134 Comparator | Dec 2023 → May 2024 | gallstones | University of Duhok | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rowachol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01765465 ↗ |
| Action | Inhibit | “to inhibit hepatic 3-hydroxy-3-methylglutaric acid(HMG)-coenzyme A(CoA) reductase” NCT01765465 ↗ |
| Modality | Other / unclassified | “Rowachol® (terpene extract)” NCT06972134 ↗ |
| Route | Oral | “200mg PO tid” NCT01765465 ↗ |